(UroToday.com) In this session, Dr. Robert Jones discussed whether there are patients with metastatic hormone-sensitive prostate cancer (mHSPC) for whom treatment with ADT is appropriate in 2021. To frame this discussion, he considered the question from a biological and humanitarian perspective. From the biology standpoint, he posited two questions. Can we predict the absolute futility of all additional interventions? And can we predict patients where additional interventions will do more harm than good? From the human standpoint, can we predict who will survive without additional interventions, i.e., die of other causes without intervening morbidity from prostate cancer?

X